EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Flow cytometric analysis of multiple myeloma cells in patients treated with high dose chemotherapy and hematopoietic stem cell transplantation



Flow cytometric analysis of multiple myeloma cells in patients treated with high dose chemotherapy and hematopoietic stem cell transplantation








(PDF emailed within 1 workday: $29.90)

Accession: 021051264

Download citation: RISBibTeXText



Related references

Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation. Clinical Lymphoma, Myeloma & Leukemia 15(11): 687-693, 2016

High-dose chemotherapy with hematopoietic stem cell transplantation for patients with advanced multiple myeloma. Onkologie 23(3): 272-274, Juni, 2000

High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Expert Review of Anticancer Therapy 6(3): 343-360, 2006

The role of high-dose chemotherapy supported by hematopoietic stem cell transplantation in patients with multiple myeloma: implications for nursing. Clinical Journal of Oncology Nursing 11(4): 579-589, 2007

High dose chemotherapy and stem cell transplantation in patients with multiple myeloma treated with a monoclonal antibody against CD20 prior to stem cell collection. Blood 96(11 Part 2): 326b, November 16, 2000

High-dose chemotherapy with autologous hematopoietic stem cell transplantation for multiple myeloma. Japanese Journal of Clinical Hematology 56(3): 279-288, 2015

Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation. International Journal of Hematology 88(2): 227-236, 2008

High dose sequential chemotherapy and autologous peripheral stem cell transplantation in patients with previously treated or untreated multiple myeloma. British Journal of Haematology 102(1): 352-353, July 1, 1998

Secondary primary malignancies in patients with multiple myeloma treated with high-dose chemotherapy and autologous blood stem cell transplantation. British Journal of Haematology 156(5): 683-686, 2012

High dose chemotherapy and hematopoietic stem cell transplantation in patients with myeloma. Polskie Archiwum Medycyny Wewnetrznej 105 Suppl: 153-154, 2002

Amifostine before high-dose melphalan and autologous hematopoietic stem cell transplantation for patients with multiple myeloma A case control analysis. Blood 98(11 Part 1): 201a, November 16, 2001

Myeloma cell contamination of peripheral blood stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantation. Journal of Cancer Research and Clinical Oncology 131(4): 214-218, 2004

Health related quality of life of multiple myeloma patients treated with high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood 92(10 SUPPL 1 PART 1-2): 728A, Nov 15, 1998

Clinical features and survival of 338 multiple myeloma patients treated with hematopoietic stem cell transplantation or conventional chemotherapy. European Journal of Haematology 96(4): 417-424, 2015

Design of the EXercise Intervention after Stem cell Transplantation (EXIST) study: a randomized controlled trial to evaluate the effectiveness and cost-effectiveness of an individualized high intensity physical exercise program on fitness and fatigue in patients with multiple myeloma or (non-) Hodgkin's lymphoma treated with high dose chemotherapy and autologous stem cell transplantation. Bmc Cancer 10(): 671-671, 2011